There just doesn’t seem to be enough time to cover everything that we got to see at the recent Scientific Sessions in San Diego. Since the ADA draws in scientists and researchers from around the world, it is the number-one place to present new findings both good and bad. In …

Medical pioneer has educated his diabetes patients on how to get blood sugars to 83mg/dl, 24 hours a day

The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.

Research will still continue due to its safety.

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.

Results from two studies demonstrate improved glycemic control, reduction in nighttime- and exercise-induced hypoglycemia with the use of hybrid closed-loop systems.

Which of the following GLP-1 agonists is not currently approved for use with basal insulin? A. Exenatide (Byetta) B. Dulaglutide (Trulicity) C. Albiglutide (Tanzeum) D. Liraglutide (Victoza) E. None of the above Did you get it right? Follow the link to find out!

Do you feel comfortable recommending an SGLT-2 Inhibitor as a second treatment option after metformin for your type 2 patients? Follow the link to see what your colleagues think.

Dr. Ralph Defronzo, MD, speaks about the current variability of diabetes medication as well as their effectiveness but lack of affordability, and he places a special emphasis on the effectiveness of triple therapy in the treatment of diabetes. Dr. Defronzo is a Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Diabetes Center in San Antonia, Texas. Dr. Defronzo is also Deputy Director of the Texas Diabetes Institute.